Wall Street analysts expect that Axovant Sciences (NASDAQ:AXON) will post earnings per share of ($0.39) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.49). Axovant Sciences posted earnings of ($0.53) per share in the same quarter last year, which suggests a positive year over year growth rate of 26.4%. The company is scheduled to issue its next earnings report on Tuesday, June 12th.
According to Zacks, analysts expect that Axovant Sciences will report full year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.32) to ($2.09). For the next financial year, analysts anticipate that the company will post earnings of ($1.83) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Axovant Sciences.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Wednesday, January 31st. ValuEngine upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Cowen reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Finally, Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $13.61.
A number of hedge funds have recently bought and sold shares of AXON. BlackRock Inc. boosted its stake in Axovant Sciences by 99.8% in the 4th quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after purchasing an additional 1,454,454 shares during the period. Millennium Management LLC boosted its stake in Axovant Sciences by 175.6% in the 1st quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock worth $1,770,000 after purchasing an additional 847,946 shares during the period. Hudson Bay Capital Management LP bought a new position in Axovant Sciences in the 4th quarter worth approximately $1,845,000. A.R.T. Advisors LLC boosted its stake in Axovant Sciences by 148.9% in the 1st quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 249,074 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Axovant Sciences by 2,519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 176,227 shares during the period. Institutional investors and hedge funds own 92.94% of the company’s stock.
Axovant Sciences traded up $0.07, reaching $1.30, on Monday, MarketBeat.com reports. 775,819 shares of the company’s stock were exchanged, compared to its average volume of 693,652. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 0.45. Axovant Sciences has a 52 week low of $1.02 and a 52 week high of $27.98. The firm has a market capitalization of $132.58 million, a PE ratio of -0.71 and a beta of -0.37.
About Axovant Sciences
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.